Search Results

You are looking at 1 - 5 of 5 items for

  • Author: Przemyslaw Twardowski x
  • Refine by Access: All x
Clear All Modify Search
Full access

CLO23-041: Cardiovascular Event Risk Following Androgen Deprivation Therapy Initiation by Personal History of Cardiovascular Events

Przemyslaw Twardowski, Stuart Atkinson, and Deborah Boldt-Houle

Full access

CLO20-063: Late Dosing of Leuprolide and Testosterone Levels >20NG/DL in Prostate Cancer Patients

Przemyslaw Twardowski, Stuart Atkinson, Deborah M. Boldt-Houle, and Raoul S. Concepcion

Full access

CLO21-014: Impact of Late Dosing on Testosterone Suppression With Two Different Leuprolide Acetate Formulations: In Situ Gel and Microsphere – an Analysis of US Clinical Data

Lucio N. Gordan, Stuart N. Atkinson, Deborah M. Boldt-Houle, and Przemyslaw W. Twardowski

Full access

Prostate Cancer

James Mohler, Robert R. Bahnson, Barry Boston, J. Erik Busby, Anthony D'Amico, James A. Eastham, Charles A. Enke, Daniel George, Eric Mark Horwitz, Robert P. Huben, Philip Kantoff, Mark Kawachi, Michael Kuettel, Paul H. Lange, Gary MacVicar, Elizabeth R. Plimack, Julio M. Pow-Sang, Mack Roach III, Eric Rohren, Bruce J. Roth, Dennis C. Shrieve, Matthew R. Smith, Sandy Srinivas, Przemyslaw Twardowski, and Patrick C. Walsh

Full access

Prostate Cancer, Version 3.2012 Featured Updates to the NCCN Guidelines

James L. Mohler, Andrew J. Armstrong, Robert R. Bahnson, Barry Boston, J. Erik Busby, Anthony Victor D’Amico, James A. Eastham, Charles A. Enke, Thomas Farrington, Celestia S. Higano, Eric Mark Horwitz, Philip W. Kantoff, Mark H. Kawachi, Michael Kuettel, Richard J. Lee, Gary R. MacVicar, Arnold W. Malcolm, David Miller, Elizabeth R. Plimack, Julio M. Pow-Sang, Mack Roach III, Eric Rohren, Stan Rosenfeld, Sandy Srinivas, Seth A. Strope, Jonathan Tward, Przemyslaw Twardowski, Patrick C. Walsh, Maria Ho, and Dorothy A. Shead

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer provide multidisciplinary recommendations for the clinical management of patients with prostate cancer. These NCCN Guidelines Insights highlight notable recent updates. Abiraterone acetate is a first-in-class hormonal agent that represents a new standard of care for patients with metastatic castration-recurrent prostate cancer who have previously received docetaxel (category 1 recommendation). Abiraterone acetate also received category 2B recommendations in the prechemotherapy setting for asymptomatic patients or symptomatic patients who are not candidates for docetaxel. The NCCN Prostate Cancer Panel also added new indications for existing agents, including the option of sipuleucel-T as second-line therapy. In addition, brachytherapy in combination with external beam radiation therapy with or without androgen deprivation therapy is now an alternative for patients with high-risk localized tumors or locally advanced disease.